|
Market Closed -
Nasdaq
20:00:00 30/10/2026 GMT
|
5-day change | 1st Jan Change | ||
| 120.39 USD | +3.07% |
|
+4.04% | +21.89% |
| 10-30 | Incyte Shares Rise After Oppenheimer Upgrade | MT |
| 10-30 | Incyte's Strong Opzelura Sales Offset by Regulatory Uncertainty, RBC Says | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Biopharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 24.54B | |||||
| 1,263B | |||||
| 658B | |||||
| 521B | |||||
| 391B | |||||
| 369B |
- Stock Market
- Stocks
- INCY Stock
- Charts Incyte Corporation
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
